The Bull Case For Amazon Stock

For the last several years, Amazon (AMZN) has been the world's second-largest retail company. Walmart (WMT) continues to dominate the retail industry with more Market News [Financhill] Smart Trading. Simplified. [A Rare Opportunity to Turn $1,000 into $461,800](~/AACAmgA~/RgRi_RF7P0ScaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTkwOSZhZD1hSFIwY0hNNkx5OXBiWE53ZFdKc2FYTm9aWEpuY205MWNDNW5iekpqYkc5MVpDNXZjbWN2WVdabVgyTS9iMlptWlhKZmFXUTlOVGd6T1NaaFptWmZhV1E5TVRFMU5DWm1hV3hsWDJsa1BUSTFORE09VwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The Joint Chiefs of Staff calls this new weapon "Unstoppable." This under-the-radar company is not yet a household name. [Our research proves that anyone who gets in now could turn $1,000 into $461,800 ](~/AACAmgA~/RgRi_RF7P0ScaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTkwOSZhZD1hSFIwY0hNNkx5OXBiWE53ZFdKc2FYTm9aWEpuY205MWNDNW5iekpqYkc5MVpDNXZjbWN2WVdabVgyTS9iMlptWlhKZmFXUTlOVGd6T1NaaFptWmZhV1E5TVRFMU5DWm1hV3hsWDJsa1BUSTFORE09VwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) Sponsored The Bull Case For Amazon Stock For the last several years, Amazon (AMZN) has been the world’s second-largest retail company. Walmart (WMT) continues to dominate the retail industry with more than three times Amazon’s sales. When it comes to e-commerce platforms, though, no one comes close to matching Amazon’s reach. It has become a ubiquitous brand used by millions of customers. […] [Continue Reading >](~/AACAmgA~/RgRi_RF7P0REaHR0cHM6Ly9maW5hbmNoaWxsLmNvbS9ibG9nL2ludmVzdGluZy90aGUtYnVsbC1jYXNlLWZvci1hbWF6b24tc3RvY2tXA3NwY0IKYRUBjRphfoyRaVIbdHJpc3RyYW1iYWxkd2luODhAZ21haWwuY29tWAQAAAAA) Check out the Seasonal Trend for FIS [View Seasonality for FIS](~/AACAmgA~/RgRi_RF7P0R1aHR0cHM6Ly9maW5hbmNoaWxsLmNvbS9zZWFyY2gvc2Vhc29uYWxpdHkvRklTP3V0bV9tZWRpdW09ZW1haWwmdXRtX3NvdXJjZT1CbG9nRGlnZXN0JnV0bV9jYW1wYWlnbj0yMDIxMDgxNl9uZXdzbGV0dGVyVwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) [Small Biotech Could Soar 1,000%](~/AACAmgA~/RgRi_RF7P0ScaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTY3MiZhZD1hSFIwY0hNNkx5OXBiWE53ZFdKc2FYTm9aWEpuY205MWNDNW5iekpqYkc5MVpDNXZjbWN2WVdabVgyTS9iMlptWlhKZmFXUTlOVEkxTnlaaFptWmZhV1E5TVRFMU5DWm1hV3hsWDJsa1BUSXlOekk9VwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) There's no sector poised to deliver bigger gains in 2021 than small-cap biotech stocks. In the past year alone... Novavax Inc jumped from $6.26 to $270.51, a gain of 3,396%. Aclaris Therapts jumped from $0.70 to $24.28 an increase of 1,583%. Vaxart Inc rocketed from $0.97 to $14.94, a 1,083% jump. [Here's the next biotech we think could soar 1,000% ](~/AACAmgA~/RgRi_RF7P0ScaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTY3MiZhZD1hSFIwY0hNNkx5OXBiWE53ZFdKc2FYTm9aWEpuY205MWNDNW5iekpqYkc5MVpDNXZjbWN2WVdabVgyTS9iMlptWlhKZmFXUTlOVEkxTnlaaFptWmZhV1E5TVRFMU5DWm1hV3hsWDJsa1BUSXlOekk9VwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) Sponsored Is Oracle Stock a Sell? Oracle Corporation (NYSE:ORCL) once lagged behind in the technological race to software supremacy, but it rose over the last decade to become a titan of industry. The database pioneer has created a cloud-based platform that is relied upon globally by enterprises and that has catalyzed a sharp rise higher in its hare price, which begs […] [Continue Reading >](~/AACAmgA~/RgRi_RF7P0Q8aHR0cHM6Ly9maW5hbmNoaWxsLmNvbS9ibG9nL2ludmVzdGluZy9pcy1vcmFjbGUtc3RvY2stYS1zZWxsVwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) [Stock Market Whiz Kid Works 1 Hour a Day. Makes Millions.](~/AACAmgA~/RgRi_RF7P0ScaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTc2OCZhZD1hSFIwY0hNNkx5OXBiWE53ZFdKc2FYTm9aWEpuY205MWNDNW5iekpqYkc5MVpDNXZjbWN2WVdabVgyTS9iMlptWlhKZmFXUTlOVFV5TUNaaFptWmZhV1E5TVRFMU5DWm1hV3hsWDJsa1BUSXpPVFk9VwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) He was living with his parents. Two years later he had $5 million to play with - all because of this 1 EXTRA INCOME strategy. [To see how he did it click here.](~/AACAmgA~/RgRi_RF7P0ScaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTc2OCZhZD1hSFIwY0hNNkx5OXBiWE53ZFdKc2FYTm9aWEpuY205MWNDNW5iekpqYkc5MVpDNXZjbWN2WVdabVgyTS9iMlptWlhKZmFXUTlOVFV5TUNaaFptWmZhV1E5TVRFMU5DWm1hV3hsWDJsa1BUSXpPVFk9VwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) Sponsored The Bull Case For Uber Stock Since Uber’s inception, the company has been at the forefront of the ridesharing conversation. Many competitors have come and gone, but few have stood toe to toe against Uber (Didi and Lyft are the two standout exceptions) even though Uber has had its fair share of struggles internally over the years. Given the company’s dominance […] [Continue Reading >](~/AACAmgA~/RgRi_RF7P0RCaHR0cHM6Ly9maW5hbmNoaWxsLmNvbS9ibG9nL2ludmVzdGluZy90aGUtYnVsbC1jYXNlLWZvci11YmVyLXN0b2NrVwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) [Buy Gold & Silver with Your IRA/401(k) Using this IRS Loophole](~/AACAmgA~/RgRi_RF7P0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTEyNTMmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpZNU5pWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk1TlRnPVcDc3BjQgphFQGNGmF-jJFpUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) Rollover your 401K to a precious metals IRA and protect yourself & family from inflation. From the #1 gold IRA Company, This free gold & silver IRA guide will show you how you can roll over your IRA or 401(k) into precious metals. Tax free & penalty-free into an IRA holding using a loophole the IRS doesn't want you to know! [Get your free guide here!](~/AACAmgA~/RgRi_RF7P0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTEyNTMmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpZNU5pWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk1TlRnPVcDc3BjQgphFQGNGmF-jJFpUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) Sponsored Will NIO Stock Go Up After Earnings? NIO has been pushing electric car technology since its founding in 2014. The company currently offers sedans, coupes, and SUVs with exceptional ranges. Management reported extraordinary revenue growth during it most recent quarter. How will the market respond to the next earnings announcement? The Bull Case For NIO NIO (NIO) has shown ample reasons for […] [Continue Reading >](~/AACAmgA~/RgRi_RF7P0RJaHR0cHM6Ly9maW5hbmNoaWxsLmNvbS9ibG9nL2ludmVzdGluZy93aWxsLW5pby1zdG9jay1nby11cC1hZnRlci1lYXJuaW5nc1cDc3BjQgphFQGNGmF-jJFpUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) [The World's First $20 Trillion Drug?](~/AACAmgA~/RgRi_RF7P0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTExOTQmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpVM01pWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk0T1RrPVcDc3BjQgphFQGNGmF-jJFpUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) One small biotech holds the key to a revolution in treating Alzheimer's. Jeff Bezos, Goldman Sachs & a Big Pharma giant have invested billions into this unknown biotech. Our research shows that anyone who gets in by August 6th, 2021 could turn every $1,000 into $1.1 million. [Click here to learn more...](~/AACAmgA~/RgRi_RF7P0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTExOTQmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpVM01pWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk0T1RrPVcDc3BjQgphFQGNGmF-jJFpUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) Sponsored What Is A Good Dividend Yield Percentage? Popular dividend-paying stocks tend to be companies found in industries that enjoy high cash flows, and ones that aren’t encumbered with the obligation to reinvest their profits back into the business. These are more likely to be mature companies, particularly those in the utilities and consumer goods sectors. What Is A Dividend Yield? When gauging […] [Continue Reading >](~/AACAmgA~/RgRi_RF7P0ROaHR0cHM6Ly9maW5hbmNoaWxsLmNvbS9ibG9nL2ludmVzdGluZy93aGF0LWlzLWEtZ29vZC1kaXZpZGVuZC15aWVsZC1wZXJjZW50YWdlVwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) [Tiny Biotech Creates $2 Trillion Drug](~/AACAmgA~/RgRi_RF7P0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTExMzYmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpRME5TWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk0TXpFPVcDc3BjQgphFQGNGmF-jJFpUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) The Wall Street Journal reports new treatment is "transforming medicine." Bill Gates writes that it could "help humanity." Ark Investments think it could be a "$2 trillion market." And one small company owns the patent on it. [This unknown biotech's stock is set to surge 46,751% ](~/AACAmgA~/RgRi_RF7P0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTExMzYmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpRME5TWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk0TXpFPVcDc3BjQgphFQGNGmF-jJFpUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) Sponsored View this email [online](~/AACAmgA~/RgRi_RF7P0QaaHR0cDovL2ZpbmFuY2hpbGwuY29tL2Jsb2dXA3NwY0IKYRUBjRphfoyRaVIbdHJpc3RyYW1iYWxkd2luODhAZ21haWwuY29tWAQAAAAA) if it doesn't display correctly. This newsletter is not financial advice. Please read our [Disclaimer](~/AACAmgA~/RgRi_RF7P0QbaHR0cDovL2ZpbmFuY2hpbGwuY29tL3Rlcm1zVwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~). To unsubscribe from Financhill, [click here](~/AACAmgA~/RgRi_RF7P0RRaHR0cDovL2ZpbmFuY2hpbGwuY29tL3Vuc3Vic2NyaWJlLzhlZjJlNmM4YmY2MTdmNDQ5N2EyYmU5NWUxOTgyNWYwLTQ0NDg1OTc3LTg2OTE1VwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~). PO Box 126 Catasauqua, PA 18032 Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory. The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email. The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: [Characteristics and Risks of Standardized Options](~/AACAmgA~/RgRi_RF7P0RFaHR0cDovL3d3dy5vcHRpb25zY2xlYXJpbmcuY29tL2Fib3V0L3B1YmxpY2F0aW9ucy9jaGFyYWN0ZXItcmlza3MuanNwVwNzcGNCCmEVAY0aYX6MkWlSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~). The Financhill.com educational training program and software services are provided to improve financial understanding. The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing. Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.